Conflict of Interest: CIRM to End Contract with Consultant Linked to Grant Recipient
By Dr. Matthew Watson
The California stem cell agency will
not renew a contract with a "special advisor" who has been
nominated to the board of directors of a firm that is sharing in a $14.5 million grant from the agency.
not renew a contract with a "special advisor" who has been
nominated to the board of directors of a firm that is sharing in a $14.5 million grant from the agency.
She is Saira Ramasastry, managing
partner of LifeSciences Advisory, LLC, of Emerald Lake Hills, Ca.
Ramasastry has worked for CIRM since May of 2010. Last month, she was
nominated to the board of Sangamo BioSciences, Inc., of Richmond, Ca.
Her responsibilities with CIRM have included "industry analysis
and consultation." Sangamo cited her experience with CIRM in its
press release on her nomination. She was also employed as a
consultant by Sangamo, according to the firm.
partner of LifeSciences Advisory, LLC, of Emerald Lake Hills, Ca.
Ramasastry has worked for CIRM since May of 2010. Last month, she was
nominated to the board of Sangamo BioSciences, Inc., of Richmond, Ca.
Her responsibilities with CIRM have included "industry analysis
and consultation." Sangamo cited her experience with CIRM in its
press release on her nomination. She was also employed as a
consultant by Sangamo, according to the firm.
Ramasastry's dual roles raise obvious
conflict of interest questions. The case highlights the issues
that can arise between CIRM and the biotech industry as the agency
moves to engage industry more closely. CIRM's response additionally
demonstrates a lack of awareness of the potential for serious
mischief or worse when dealing with consultants.
conflict of interest questions. The case highlights the issues
that can arise between CIRM and the biotech industry as the agency
moves to engage industry more closely. CIRM's response additionally
demonstrates a lack of awareness of the potential for serious
mischief or worse when dealing with consultants.
The California Stem Cell Report asked
CIRM on May 6 for comment on the Sangamo-Ramasastry matter. The
questions included whether Ramasastry disclosed to CIRM her work for
Sangamo and whether CIRM took any action per the agency's conflict of
interest code. CIRM did not respond to the question of whether
Ramasastry ever disclosed her ties to Sangamo, which expects to
receive $5.2 million from the CIRM grant if it runs a full four
years.
CIRM on May 6 for comment on the Sangamo-Ramasastry matter. The
questions included whether Ramasastry disclosed to CIRM her work for
Sangamo and whether CIRM took any action per the agency's conflict of
interest code. CIRM did not respond to the question of whether
Ramasastry ever disclosed her ties to Sangamo, which expects to
receive $5.2 million from the CIRM grant if it runs a full four
years.
Here is the text of CIRM's reply today
from spokesman Kevin McCormack.
from spokesman Kevin McCormack.
"Saira Ramasastry was an
independent contractor. As required by law, we do ask independent
consultants to complete Form 700s(statements of economic interests)
if they participate in an agency decision making role. Her role did
not fall into that category - she was identified as a 'special
advisor' in connection with our external review process - and so she
did not have to fill out a Form 700. Her contract with CIRM comes to
an end at the end of June, and she will not be elected to Sangamo's
board of directors until July. Obviously once she is a member of the
Sangamo board she will not be consulting or advising CIRM because of
our strict conflict of interest rules."
(Editor's note: The board election is
June 21, according to the company, not July.)
June 21, according to the company, not July.)
Our take: CIRM is heavily dependent on
outside contractors. Expenditures for their services are the second
largest item in CIRM's operational budget, exceeded only by salaries
and benefits of regular employees. The responsibilities of outside
contractors cover a wide range of sensitive tasks including computer
system security, development of software that deals with proprietary
information from grant recipients, analysis of confidential business
operations of grant and loan applicants and much more.
outside contractors. Expenditures for their services are the second
largest item in CIRM's operational budget, exceeded only by salaries
and benefits of regular employees. The responsibilities of outside
contractors cover a wide range of sensitive tasks including computer
system security, development of software that deals with proprietary
information from grant recipients, analysis of confidential business
operations of grant and loan applicants and much more.
The agency needs to know who their
consultants are working for besides CIRM. Whether they make decisions
for CIRM is beside the point. Gathering information that is not
normally accessible to the public can be extremely valuable to
businesses and their competitors as well as applicants for
CIRM's $3 billion. In Ramasastry's case, she was privy to a great
deal of confidential or economically useful information during her work on CIRM's external
review and likely much more.
consultants are working for besides CIRM. Whether they make decisions
for CIRM is beside the point. Gathering information that is not
normally accessible to the public can be extremely valuable to
businesses and their competitors as well as applicants for
CIRM's $3 billion. In Ramasastry's case, she was privy to a great
deal of confidential or economically useful information during her work on CIRM's external
review and likely much more.
The use of California's Form 700 is
hardly adequate to assess conflict of interest issues involving
private consultants. The form was developed in the 1970s to deal with
elected officials primarily and provides only the grossest sort of
look at financial holdings and income.
hardly adequate to assess conflict of interest issues involving
private consultants. The form was developed in the 1970s to deal with
elected officials primarily and provides only the grossest sort of
look at financial holdings and income.
CIRM's current move to embrace industry
requires more scrutiny of conflicting interests – not less. NextThursday the CIRM board will deal with some of its conflict ofinterest rules. It is fine opportunity to ask for a sharper analysis
of conflict issues and consultants with an eye to strengthening CIRM
regulations and ensuring protection of the agency and its grantees'
work – not to mention the interests of the people of California.
requires more scrutiny of conflicting interests – not less. NextThursday the CIRM board will deal with some of its conflict ofinterest rules. It is fine opportunity to ask for a sharper analysis
of conflict issues and consultants with an eye to strengthening CIRM
regulations and ensuring protection of the agency and its grantees'
work – not to mention the interests of the people of California.
Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Related Post
- Tracking the Fruits of California Stem Cell Agency Research - September 1st, 2013
- UCLA Snags $3.6 Million from California Stem Cell Agency - September 1st, 2013
- Stem Cell Agency Seeks Stronger Ties with Possible Industry Funding Partners - September 1st, 2013
- UCLA Takes Four of 13 Awards Today; One Business Wins - September 1st, 2013
- $41 Million in California Stem Cell Grants Virtually Approved - September 1st, 2013
- Stem Cell Agency Pays Tribute to the Late Duane Roth - September 1st, 2013
- Skin in California’s Stem Cell Game - September 1st, 2013
- California Stem Cell Agency's $150,000 Search for Its Financial Future - August 25th, 2013
- California Stem Cell Researchers to Receive $70 Million Next Week - August 25th, 2013
- Flim-Flam Stem Cell Artists Targeted by CIRM - August 25th, 2013
- California Stem Cell Agency Spending: Where the Money Is Going - August 25th, 2013
- A $2 Million Bill: Outside Contracting by California Stem Cell Agency - August 25th, 2013
- New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency - August 25th, 2013
- Bonilla: Veto of Pay-for-Eggs Bill Shows Troubling Mindset - August 18th, 2013
- 'Butter and Eggs Money" and a Gubernatorial Veto - August 18th, 2013
- California Gov. Jerry Brown Vetoes Pay-for-Eggs Legislation - August 18th, 2013
- A $6 Billion Question: Progress of the California Stem Cell Agency - August 18th, 2013
- Duane Roth: Ecumenical Innovator for San Diego and Biotech - August 18th, 2013
- Stem Cell Agency's Duane Roth Eulogized at Memorial Services - August 18th, 2013
- 'Paradigm Shift' -- Researchers as Patient Advocates? - August 18th, 2013
- California Stem Cell Agency on Lacks: Informed Consent Cannot Remove All Questions - August 11th, 2013
- Californians Top List of Stem Cell Honorees - August 11th, 2013
- The Henrietta Lacks Story and Eggs, Money and Motherhood - August 11th, 2013
- Skloots, Collins and More on Henrietta Lacks' Cell Line Deal - August 11th, 2013
- Memorial Services Friday for Duane Roth, Co-vice chairman of the California Stem Cell Agency - August 11th, 2013
- CIRM's Roth Dies Following Bike Accident - August 11th, 2013
- Pay-for-Eggs Legislation Now Before California Gov. Jerry Brown - August 4th, 2013
- Comment re Pay-for-Eggs Item and Forbes Article - August 4th, 2013
- Pay-for-Eggs Legislation: A Comment on Risk - August 4th, 2013
- Skimpy Coverage of Alpha Clinic Concept Approval - August 4th, 2013
- California Stem Cell Agency Looking for New Home in Two Years - August 4th, 2013
- California Stem Cell Official Duane Roth in Improving Condition - July 28th, 2013
- Another $23 Million to Recruit Star Stem Cell Scientists to California - July 28th, 2013
- California Stem Cell Agency Launches $70 Million Alpha Stem Cell Clinic Project - July 28th, 2013
- Coming Up: Live Coverage of Today's California Stem Cell Meeting - July 28th, 2013
- Stem Cell Lines and Paid-for Eggs: Stem Cell Agency Delays Action on Easing Restrictions - July 28th, 2013
- $70 Million Alpha Stem Cell Clinic Project Garners Mainstream Media Attention - July 28th, 2013
- UCLA Researcher Calls for Easing of Restrictions on Stem Cell Lines Derived from Eggs From Paid Providers - July 28th, 2013
- California Stem Cell Agency to Commit 20 Percent of Remaining Cash - July 21st, 2013
- Paying for Human Eggs, Ivan Illich and Jerry Brown - July 21st, 2013
- California's $70 Million 'Alpha' Stem Cell Clinic Plan Headed for Approval Next Week - July 21st, 2013
- TV News Piece on Pay-for-Eggs Airs in Los Angeles, San Francisco - July 14th, 2013
- Shestack Resignation Letter: Heartfelt and Eloquent - July 14th, 2013
- Veto Campaign Launched on California Pay-For-Eggs Bill - July 14th, 2013
- Sacramento Mental Health Advocate Appointed to Stem Cell Agency Board - July 14th, 2013
- California Stem Cell Merger: Capricor and Niles Therapeutics - July 14th, 2013
- Pay-for-Eggs Legislation: Strange Bedfellows and Existential Questions - July 14th, 2013
- "Comfort News" for California's Stem Cell Research Effort - July 14th, 2013
- HIV Clinical Trial Hailed by California Stem Cell Agency - July 14th, 2013
- Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments - July 14th, 2013
- California Legislation Removing Ban on Payments for Eggs for Research Heads to Governor - July 14th, 2013
- California Legislation, Human Egg Sales and Profits - July 7th, 2013
- Challenge to WARF hESC Patents Cites Recent U.S. Supreme Court Decision - July 7th, 2013
- Cost of a Stem Cell Therapy? An Estimated $512,000 - June 30th, 2013
- Bluebird and Banking: Media Pluses for California Stem Cell Agency - June 30th, 2013
- International team submits IND application - June 23rd, 2013
- Pay-For-Eggs Legislation Draws More Media Attention - June 23rd, 2013
- Compensation for Human Eggs Approved by Key California Senate Committee, But Not For CIRM Researchers - June 16th, 2013
- Merksamer Makes Only Bid For Stem Cell Agency Lobbying Contract - June 16th, 2013
- Cellular Dynamics: California Stem Cell Agency Recipient Plans $57 Million IPO - June 9th, 2013
- Light Coverage of Cellular Dynamics IPO But One Exec Says It's Good for Stem Cell Biz - June 9th, 2013
- Pomeroy on Doing the Right Thing and Foster Care - June 9th, 2013
- Vatican Funding for California Stem Cell Agency? - June 2nd, 2013
- Bluebird bio of Massachusetts Still Waiting for California Stem Cell Money - June 2nd, 2013
- California's Alpha Stem Cell Clinics: Open in 2014, Six to Eight Locations - June 2nd, 2013
- Monterey Newspaper Chides California Stem Cell Agency - June 2nd, 2013
- Trounson Proposes $70 Million, Fast-Track Stem Cell Clinic Plan for California - June 2nd, 2013
- $70 Million Alpha Stem Cell Clinic Proposal Draws Reader Comment - June 2nd, 2013
- Sacramento Bee: Ongoing Conflict Problems No Help for Future Funding of Stem Cell Agency - June 2nd, 2013
- Multimillion Dollar Carrots for Stem Cell Research in California - May 26th, 2013
- California Stem Cell Agency: 5 Percent Budget Increase for Coming Fiscal Year - May 26th, 2013
- $36 Million Recruitment: Names of Researchers Being Lured to California - May 26th, 2013
- Stem Cell Agency Approves $36 million to Recruit Six Scientists to California - May 26th, 2013
- California Stem Cell Agency to Court Patient Groups This Summer - May 26th, 2013
- Nature Reports on Lee Hood Conflict Case - May 26th, 2013
- Grant Reviewer Conflict in $40 Million Round at California Stem Cell Agency - May 26th, 2013
- Text of CIRM Comments on Lee Hood Questions - May 26th, 2013
- Replicating Oregon Cloning in California: Views on the Legality - May 19th, 2013
- Oregon-style Stem Cell Cloning Research Illegal in California: No Pay for Eggs in Golden State - May 19th, 2013
- Weissman Says Oregon-style Stem Cell Research Could be Done in California - May 19th, 2013
Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research